Disodium Edetate (Dihydrate)

Blenrep is used to treat adults with relapsed or refractory multiple myeloma (MM) who have received at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. It is used in combination with bortezomib and dexamethasone. Blenrep is given by intravenous infusion every 3 weeks. Blenrep (belantamab mafodotin) was initially approved by the FDA in August 2020 under the accelerated approval designation. On March 20, 2023, the FDA withdrew approval after the DREAMM-3 clinical trial failed to meet its primary endpoint. On October 23, 2025, Blenrep was reapproved for r/r MM in combination with bortezomib and dexamethasone, supported by data from the DREAMM-7 phase III clinical trial , which reported: A 51% reduction in the risk of death with Blenrep plus bortezomib/dexamethasone versus daratumumab therapy Tripled progression-free survival from 10.4 to 31.3 months.

Blenrep is used to treat adults with relapsed or refractory multiple myeloma (MM) who have received at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. It is used in combination with bortezomib and dexamethasone. Blenrep is given by intravenous infusion every 3 weeks. Blenrep (belantamab mafodotin) was initially approved by the FDA in August 2020 under the accelerated approval designation. On March 20, 2023, the FDA withdrew approval after the DREAMM-3 clinical trial failed to meet its primary endpoint. On October 23, 2025, Blenrep was reapproved for r/r MM in combination with bortezomib and dexamethasone, supported by data from the DREAMM-7 phase III clinical trial , which reported: A 51% reduction in the risk of death with Blenrep plus bortezomib/dexamethasone versus daratumumab therapy Tripled progression-free survival from 10.4 to 31.3 months.

Disodium Edetate (Dihydrate) is contraindicated in conditions like Renal diseases.

The severe or irreversible adverse effects of Disodium Edetate (Dihydrate), which give rise to further complications include Renal tubular changes, Engorgement of reticuloendothelial cells, Coarse eosinophilic granules, Hemorrhage. Disodium Edetate (Dihydrate) produces potentially life-threatening effects which include Convulsions, Arrhythmias, Cardiac Arrest, Hypocalcemia. which are responsible for the discontinuation of Disodium Edetate (Dihydrate) therapy. The symptomatic adverse reactions produced by Disodium Edetate (Dihydrate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Weakness, Fatigue, Nausea, Diarrhea, Fever, Chills, Hypotension, Dermatitis, Local burning, Abdominal cramping pain, Paresthesia, Tetany, Reaction at injection site, Respiratory arrest.

Blenrep carries a Boxed Warning for eye problems.

Blenrep carries a Boxed Warning for eye problems.

0.389 to 0.583 mg/kg.min (0.49 (0.486)) As recommended. IV Inf — For 2-3 Hours for 5 Days

40 to 70 mg/kg (55 (55)) 24 hourly Infusion — Infuse over 3 or more hrs

No neonatal dosage information is recorded for this medicine yet.

Tell your healthcare provider about all medicines you take, including prescription medications, over-the-counter medicines, vitamins and supplements, and herbal products. No formal drug interaction studies have been performed with Blenrep.

Inf